NCT05128734View on ClinicalTrials.gov

Temozolomide Monotherapy or in Combination With Olaparib in Patients With Triple Negative Breast Cancer (TNBC)

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

September 1, 2025

Primary Completion Date

July 1, 2027

Study Completion Date

July 1, 2028

Conditions
Breast Cancer Triple Negative
Interventions
DRUG

Temozolomide

Temozolomidewill be administered orally for 7 days (D) every 21 days until progression of the disease in both arms.

DRUG

Olaparib

Olaparib will be administered orally twice daily in treatment arm 2.

Trial Locations (1)

T2N 5G2

Arthur J.E. Child Comprehensive Cancer Centre, Calgary

All Listed Sponsors
lead

AHS Cancer Control Alberta

OTHER